Lynn Anne Bristol

Array ( [id] => 18020667 [patent_doc_number] => 20220372166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER [patent_app_type] => utility [patent_app_number] => 17/755196 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17755196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19106033 [patent_doc_number] => 11959118 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc-region [patent_app_type] => utility [patent_app_number] => 17/075343 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 40 [patent_no_of_words] => 32802 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17075343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711966 [patent_doc_number] => 20210079113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO [patent_app_type] => utility [patent_app_number] => 17/071121 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112810 [patent_doc_number] => 20240124560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION [patent_app_type] => utility [patent_app_number] => 17/768701 [patent_app_country] => US [patent_app_date] => 2020-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18994532 [patent_doc_number] => 11911348 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Therapeutic agent for cancer [patent_app_type] => utility [patent_app_number] => 17/066744 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 4187 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17066744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725915 [patent_doc_number] => 20230340157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => MONOSPECIFIC AND MULTI-SPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/763582 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725915 [patent_doc_number] => 20230340157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => MONOSPECIFIC AND MULTI-SPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/763582 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020648 [patent_doc_number] => 20220372147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => BINDING MODULES COMPRISING MODIFIED EHD2 DOMAINS [patent_app_type] => utility [patent_app_number] => 17/762463 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036234 [patent_doc_number] => 20220380449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHODS OF TREATING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) USING IL-17RA ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/642130 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036234 [patent_doc_number] => 20220380449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHODS OF TREATING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) USING IL-17RA ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/642130 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657441 [patent_doc_number] => 20210054077 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 16/996899 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16614005 [patent_doc_number] => 20210032658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => MND PROMOTER CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/987768 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18685205 [patent_doc_number] => 11780923 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => PD-L1 antibody, antigen-binding fragment thereof and medical application thereof [patent_app_type] => utility [patent_app_number] => 16/947583 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 11451 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 233 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16947583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482452 [patent_doc_number] => 20200376052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS [patent_app_type] => utility [patent_app_number] => 16/985607 [patent_app_country] => US [patent_app_date] => 2020-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16985607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452619 [patent_doc_number] => 20200362045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/985868 [patent_app_country] => US [patent_app_date] => 2020-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16985868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582874 [patent_doc_number] => 20210017276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => ANTI-TIGIT ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/939883 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16622510 [patent_doc_number] => 20210041163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => METHOD FOR SELECTING ANTIBODIES WITH MODIFIED FCRN INTERACTION [patent_app_type] => utility [patent_app_number] => 16/939659 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882765 [patent_doc_number] => 20220298242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => Bispecific Antibody Targeting CD3 and CD20 and Use Thereof [patent_app_type] => utility [patent_app_number] => 17/636440 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882765 [patent_doc_number] => 20220298242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => Bispecific Antibody Targeting CD3 and CD20 and Use Thereof [patent_app_type] => utility [patent_app_number] => 17/636440 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420646 [patent_doc_number] => 20200345844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => COMBINED THERAPEUTIC USE OF ANTIBODIES AND IMMUNOGLOBULIN G-DEGRADING ENZYMES [patent_app_type] => utility [patent_app_number] => 16/932588 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932588 [rel_patent_id] =>[rel_patent_doc_number] =>)